Physician profile
David Pocoski
NPI 1235194754
$3,983.13
in general payments reported to CMS, 2019-2025
30 companies · $71.81 in 2025
The $71.81 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $390 · 2021: $980 · 2022: $845 · 2023: $516 · 2024: $736 · 2025: $71.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,011.94 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $672.78 | 2019-2023 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $371.00 | 2021-2024 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $263.68 | 2019-2022 | |
| Pfizer INC. | $224.81 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.93 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.81 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $126.26 | 2019-2021 | |
| Amarin Pharma, INC. | $123.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $119.79 | 2022-2023 | |
| Esperion Therapeutics, INC. | $82.93 | 2020-2024 | Nexletol |
| Sun Pharmaceutical Industries INC. | $78.80 | 2021-2024 | |
| Abbott Laboratories | $72.34 | 2023-2024 | Freestyle Libre 3 |
| Cvrx, INC. | $66.05 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $54.02 | 2021-2025 | Breztri, Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.17 | 2023-2024 | Mounjaro, Zepbound |
| Regeneron Healthcare Solutions, INC. | $42.93 | 2019 | |
| Incyte Corporation | $33.21 | 2021 | |
| Smith+Nephew, INC. | $32.76 | 2024 | Renasys Go V2 Home |
| Actelion Pharmaceuticals US, INC. | $29.22 | 2022 | |
| Convatec INC. | $29.15 | 2023 | |
| Kestra Medical Technology Services, INC. | $24.57 | 2024 | Assure Wcd |
| Astellas Pharma US INC | $23.70 | 2021 | |
| Biofrontera INC. | $21.15 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Leo Pharma INC. | $21.13 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.97 | 2023 | Arcalyst |
| Dexcom, INC. | $15.20 | 2022 | |
| Abbvie INC. | $14.58 | 2021 | |
| Antares Pharma, INC. | $12.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pocoski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.